Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

The abstract describes 6 participants taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

SEMA-VR CardioLink-15 was a randomized translational trial of usual care vs semaglutide for 6 months in 46 participants with either type 2 diabetes and/or obesity plus atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk factors.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The methods mention a period of 6 months.

Vascular regenerative cells were enumerated using multi-parametric flow cytometry for high aldehyde dehydrogenase activity (ALDHhi) and lineage-specific cell surface marker expression.

The primary endpoint was the 6-month change in VR cell content.

What Was Measured

PubMed files the paper under topics including Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Stem Cells, Atherosclerosis, Obesity, Hypoglycemic Agents and Regeneration.

The authors tagged it with the keywords Cardiometabolic disease, GLP-1 receptor agonists, Progenitor cell and Semaglutide.

What This Means in Plain Language

The paper is a randomized study of Semaglutide in 6 participants over 6 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (European heart journal), a journal based in England.

More context: the Semaglutide compound page, all human trials.